Feeds:
Posts
Comments

Archive for the ‘Bone loss’ Category

New drugs effective against bone problems caused by hormone treatment of prostate cancer

Posted in Bone loss, Treatment news, tagged , , , , , , , , , , , , , , , on August 5, 2010| Leave a Comment »

URO TODAY: New drugs – still being trialled – are proving effective treatment of prostate cancer bone metastases and prevention of fractures associated with androgen deprivation therapy. READ MORE>

Read Full Post »

Prostate cancer patients at risk of losing bone mineral content

Posted in Bone loss, tagged , , , , , , on July 18, 2010| Leave a Comment »

BETTER HEALTH RESEARCH: Prostate cancer patients may be at an increased risk of suffering from bone mineral content loss compared to men who are cancer-free. READ MORE>

Read Full Post »

$1100-per-dose bone fracture preventing drug gets FDA approval

Posted in Bone loss, PROSTATE CANCER, tagged , , , , , , , , , , , , , , on June 12, 2010| Leave a Comment »

REUTERS: The US Food and Drug Administration has approved the sale of Amgen Inc’s osteoporosis drug Prolia – denosumab – to help prevent fractures in advanced cancer patients just days after the medicine received European approval. It will cost $US825 per 60 milligram injection. READ MORE>

Read Full Post »

Radiotherapy prostate patients face risk of hip fracture

Posted in Bone loss, PROSTATE CANCER, Radiotherapy, tagged , , , , , , , , on June 3, 2010| Leave a Comment »

URO TODAY: Patients undergoing three dimensional external beam radiation therapy for prostate cancer may be at an increased risk of hip fracture and could benefit from additional measures to improve bone health following treatment. READ MORE>

Read Full Post »

Study shows generic drug prevents bone loss in prostate cancer patients

Posted in Bone loss, Hormone therapy, PROSTATE CANCER, PROSTATE RESEARCH, tagged , , , , , , , , , , , , , , on May 26, 2010| Leave a Comment »

NEW PROSTATE CANCER INFO-LINK: A new study has shown that the generically available, oral, bisphosphonate risedronate (Actonel) can prevent bone loss and related effects in patients receiving hormonal therapy for prostate cancer. READ MORE>

Read Full Post »

Fracture-reducing drug for prostate cancer patients also cuts down hormone therapy hot flushes

Posted in Bone loss, Hormone therapy, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged , , , , , , , , , , , , , , , on October 18, 2009| Leave a Comment »

URO TODAY: A fracture-reducing drug called toremifene has a useful side effect when used on prostate cancer patients – it significantly reduces hot flushes caused by hormone therapy. READ MORE>

Read Full Post »

False balls that release bone-loss drugs may make testicle removal viable option again

Posted in Bone loss, PROSTATE CANCER, PROSTATE RESEARCH, Testosterone treatment, Treatment news, tagged , , , , , , , , , , , , , , on September 15, 2009| Leave a Comment »

URO TODAY: Testicular prostheses that slow-release drugs to combat bone loss in men being treated for advanced prostate cancer, have the potential to restore testes removal as a viable option for testosterone control. READ MORE>

Read Full Post »

Bayer and Norwegian company go ahead with new drug to treat bone loss in prostate cancer patients

Posted in Bone loss, PROSTATE CANCER, Treatment news, tagged , , , , , , , , , , , on September 6, 2009| Leave a Comment »

NORWAY POST: Alpharadin, a new drug that treats men with hormone-refractory prostate cancer that has spread to the bone, will be developed by a Norwegian cancer therapeutics company and global drugs giant Bayer. READ MORE>

Read Full Post »

Bone loss blocker cuts death rate in men with metastatic prostate cancer

Posted in Bone loss, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged , , , , , , , , , , , , , , , , on August 30, 2009| Leave a Comment »

CANCER CONSULTANTS.COM: A drug treatment called Bonefos (sodium clodronate) – that blocks the function of the cells which reabsorb bone – reduces the risk of death by 23% in men with metastatic prostate cancer, report UK researchers. READ MORE>

Read Full Post »

Bone treatment drug cuts death risk in men with metastatic prostate cancer

Posted in Bone loss, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged , , , , , , , , , , , , , on August 26, 2009| Leave a Comment »

CANCER CONSULTANTS: Clodronate reduces the risk of death by 23% in men with metastatic prostate cancer, according to the results of a study published in The Lancet Oncology. Clodronate belongs to a class of drugs called bisphosphonates, which are used to treat or prevent bone complications. READ MORE>

Read Full Post »

Older Posts »